Search
Fluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Categories: P-glycoprotein inducers, P-glycoprotein substratesNiclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesPranlukast
go.drugbank.com/drugs/DB01411InvestigationalPranlukast is a cysteinyl leukotriene receptor-1 antagonist. … It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsGallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[A225396] In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA). … Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions
Categories: Compounds used in a research, industrial, or household settingNafamostat
go.drugbank.com/drugs/DB12598InvestigationalThe use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.
Synonyms: p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidineDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigational[L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL). … [A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription
Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-oneCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InducersVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … Since June 2016, Velpatasvir has been available as a fixed dose combination product with [DB08934], as the commercially available product Epclusa.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.
Methscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index